Exclusive: Lonza in bid to acquire Catalent - sources | Reuters
NEW YORK/FRANKFURT Swiss specialty chemicals and life sciences company Lonza Group AG ( LONN.S ) has offered to acquire U.S.
NEW YORK/FRANKFURT Swiss specialty chemicals and life sciences company Lonza Group AG (LONN.S) has offered to acquire U.S. drug delivery technology company Catalent Inc (CTLT.N), three people familiar with the matter said this week.
The deal would expand Lonza's life sciences capabilities, allowing it to produce a wider range of molecules used in active pharmaceutical ingredients and drug delivery. Shares of Catalent rose as much as 12 percent on the news, giving it a market capitalization of close to $4 billion.
Catalent and Lonza have so far failed to agree on the price, and there is no certainty that their negotiations will continue, the people said. Lonza, which is keen on an acquisition, may decide to pursue other targets, one of the people added.
The sources asked not to be identified because the discussions were confidential. Lonza and Catalent did not immediately respond to requests for comment.
Lonza has been expanding its presence in the United States in recent years, buying up small biopharmaceutical companies and, in 2011, acquiring chemical maker Arch Chemicals for $1.4 billion. Lonza has a market capitalization of 8.7 billion Swiss Francs ($9 billion).
Based in Somerset, New Jersey, Catalent provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It has 31 facilities worldwide and generated more than $1.8 billion in revenue in 2015.
In 2007, private equity firm Blackstone Group LP (BX.N) acquired Catalent from Cardinal Health Inc (CAH.N) for $3.3 billion. Blackstone took Catalent public in 2014 and still owns about a fifth of the company.
(Reporting by Greg Roumeliotis in New York and Arno Schuetze in Frankfurt; Additional reporting by Ludwig Burger in Frankfurt and Carl O'Donnell and Olivia Oran in New York; Editing by Richard Chang and Tom Brown)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Confusion reigns over UK's travel advisory nod to Covishield even as India absent on eligibility list
The UK's Department of Health and Social Care (DHSC) have said on Wednesday that they are unable to confirm this and will require further clarifications
AUKUS is a big deal in Indo-Pacific architecture, and it will complement, not diminish the importance of Quad
It is obvious that China's military aggressiveness, bullying of the nations in Indo-Pacific necessitated a response, and the 'historic' security alliance is aimed at mitigating the challenges
The new security alliance is likely to be seen as a provocative move by China, which has repeatedly lashed out at Joe Biden as he's sought to refocus US foreign policy on the Pacific